NEW YORK, Sept 19 - Compugen (Nasdaq: CGEN) of Tel Aviv, Israel announced Tuesday the release of Z3, a high-throughput 2 dimensional gel electrophoresis analysis system, marking the company's first foray into the burgeoning proteomics market.

2D gel electrophoresis is the method of choice for separating complex mixtures of proteins, the first step in the typical proteomics research workflow. However, the 2D gel technique is only partially exploited due to difficulties in reproducing the technique and analyzing the results.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.